# Lemaitre Vascular Inc: financial statements, quarterly

LMAT · Nasdaq · CIK 1158895 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lmat.md) · [Financials](/companies/lmat/financials.md) · [Filings](/companies/lmat/filings.md) · [Insiders](/companies/lmat/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lmat/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [47.4](/filings/0001437749-24-034124.md) | [48.9](/filings/0001437749-24-006037.md) | [53.5](/filings/0001437749-24-015899.md) | [55.8](/filings/0001437749-24-025466.md) | [54.8](/filings/0001437749-24-034124.md) | [55.7 d](/filings/0001193125-26-073360.md) | [59.9](/filings/0001193125-26-207500.md) | [64.2](/filings/0001193125-26-333762.md) | [61.0](/filings/0001193125-25-270981.md) | [64.5 d](/filings/0001193125-26-073360.md) | [66.6](/filings/0001193125-26-207500.md) | [70.4](/filings/0001193125-26-333762.md) |
| Cost of revenue | $m | [16.6](/filings/0001437749-24-034124.md) | [15.6 d](/filings/0001193125-26-073360.md) | [16.8](/filings/0001437749-25-015479.md) | [17.4](/filings/0001437749-25-024936.md) | [17.6](/filings/0001193125-25-270981.md) | [17.1 d](/filings/0001193125-26-073360.md) | [18.5](/filings/0001193125-26-207500.md) | [19.3](/filings/0001193125-26-333762.md) | [15.1](/filings/0001193125-25-270981.md) | [18.3 d](/filings/0001193125-26-073360.md) | [18.2](/filings/0001193125-26-207500.md) | [19.6](/filings/0001193125-26-333762.md) |
| Gross profit | $m | [30.8](/filings/0001437749-24-034124.md) | [33.3](/filings/0001437749-24-006037.md) | [36.7](/filings/0001437749-25-015479.md) | [38.5](/filings/0001437749-25-024936.md) | [37.2](/filings/0001193125-25-270981.md) | [38.6 d](/filings/0001193125-26-073360.md) | [41.4](/filings/0001193125-26-207500.md) | [45.0](/filings/0001193125-26-333762.md) | [46.0](/filings/0001193125-25-270981.md) | [46.2 d](/filings/0001193125-26-073360.md) | [48.4](/filings/0001193125-26-207500.md) | [50.8](/filings/0001193125-26-333762.md) |
| Research and development | $m | [4.2](/filings/0001437749-24-034124.md) | [4.4 d](/filings/0001193125-26-073360.md) | [4.1](/filings/0001437749-25-015479.md) | [4.3](/filings/0001437749-25-024936.md) | [3.7](/filings/0001193125-25-270981.md) | [3.6 d](/filings/0001193125-26-073360.md) | [4.1](/filings/0001193125-26-207500.md) | [3.5](/filings/0001193125-26-333762.md) | [3.0](/filings/0001193125-25-270981.md) | [3.5 d](/filings/0001193125-26-073360.md) | [4.1](/filings/0001193125-26-207500.md) | [4.8](/filings/0001193125-26-333762.md) |
| Operating income | $m | [9.2](/filings/0001437749-24-034124.md) | [10.2](/filings/0001437749-24-006037.md) | [11.9](/filings/0001437749-25-015479.md) | [14.4](/filings/0001437749-25-024936.md) | [13.1](/filings/0001193125-25-270981.md) | [12.9 d](/filings/0001193125-26-073360.md) | [12.6](/filings/0001193125-26-207500.md) | [16.1](/filings/0001193125-26-333762.md) | [20.3](/filings/0001193125-25-270981.md) | [18.8 d](/filings/0001193125-26-073360.md) | [17.8](/filings/0001193125-26-207500.md) | [20.4](/filings/0001193125-26-333762.md) |
| Interest expense | $m | not reported | not reported | [0.0](/filings/0001437749-25-015479.md) | [0.0](/filings/0001437749-25-024936.md) | [0.0](/filings/0001193125-25-270981.md) | [0.2 d](/filings/0001193125-26-073360.md) | [1.3](/filings/0001193125-26-207500.md) | [1.3](/filings/0001193125-26-333762.md) | [1.3](/filings/0001193125-25-270981.md) | [1.3 d](/filings/0001193125-26-073360.md) | [1.3](/filings/0001193125-26-207500.md) | [1.3](/filings/0001193125-26-333762.md) |
| Income tax | $m | [2.3](/filings/0001437749-24-034124.md) | [2.8 d](/filings/0001193125-26-073360.md) | [2.9](/filings/0001437749-25-015479.md) | [3.7](/filings/0001437749-25-024936.md) | [3.4](/filings/0001193125-25-270981.md) | [2.8 d](/filings/0001193125-26-073360.md) | [3.2](/filings/0001193125-26-207500.md) | [4.3](/filings/0001193125-26-333762.md) | [5.2](/filings/0001193125-25-270981.md) | [4.7 d](/filings/0001193125-26-073360.md) | [4.0](/filings/0001193125-26-207500.md) | [5.1](/filings/0001193125-26-333762.md) |
| Net income | $m | [7.5](/filings/0001437749-24-034124.md) | [8.5](/filings/0001437749-24-006037.md) | [9.9](/filings/0001193125-25-270981.md) | [11.8](/filings/0001193125-25-270981.md) | [11.1](/filings/0001193125-25-270981.md) | [11.2 d](/filings/0001193125-26-073360.md) | [11.0](/filings/0001193125-26-333762.md) | [13.8](/filings/0001193125-26-333762.md) | [17.4](/filings/0001193125-25-270981.md) | [15.6 d](/filings/0001193125-26-073360.md) | [15.7](/filings/0001193125-26-333762.md) | [17.1](/filings/0001193125-26-333762.md) |
| Diluted EPS | $ per share | [0.33](/filings/0001437749-24-034124.md) | [0.38](/filings/0001437749-24-006037.md) | [0.44](/filings/0001437749-25-015479.md) | [0.52](/filings/0001437749-25-024936.md) | [0.49](/filings/0001193125-25-270981.md) | not reported | [0.48](/filings/0001193125-26-207500.md) | [0.60](/filings/0001193125-26-333762.md) | [0.75](/filings/0001193125-25-270981.md) | not reported | [0.68](/filings/0001193125-26-207500.md) | [0.74](/filings/0001193125-26-333762.md) |
| Basic EPS | $ per share | [0.34](/filings/0001437749-24-034124.md) | [0.38](/filings/0001437749-24-006037.md) | [0.44](/filings/0001437749-25-015479.md) | [0.53](/filings/0001437749-25-024936.md) | [0.50](/filings/0001193125-25-270981.md) | not reported | [0.49](/filings/0001193125-26-207500.md) | [0.61](/filings/0001193125-26-333762.md) | [0.77](/filings/0001193125-25-270981.md) | not reported | [0.69](/filings/0001193125-26-207500.md) | [0.75](/filings/0001193125-26-333762.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [18.1](/filings/0001437749-23-030613.md) | [24.3](/filings/0001437749-25-005637.md) | [26.6](/filings/0001437749-24-015899.md) | [22.3](/filings/0001437749-24-025466.md) | [21.0](/filings/0001437749-24-034124.md) | [25.6](/filings/0001193125-26-073360.md) | [25.3](/filings/0001437749-25-015479.md) | [27.2](/filings/0001437749-25-024936.md) | [25.5](/filings/0001193125-25-270981.md) | [28.2](/filings/0001193125-26-333762.md) | [26.9](/filings/0001193125-26-207500.md) | [26.6](/filings/0001193125-26-333762.md) |
| Current assets | $m | [182](/filings/0001437749-23-030613.md) | [195](/filings/0001437749-25-005637.md) | [203](/filings/0001437749-24-015899.md) | [213](/filings/0001437749-24-025466.md) | [227](/filings/0001437749-24-034124.md) | [402](/filings/0001193125-26-073360.md) | [408](/filings/0001437749-25-015479.md) | [430](/filings/0001437749-25-024936.md) | [452](/filings/0001193125-25-270981.md) | [468](/filings/0001193125-26-333762.md) | [478](/filings/0001193125-26-207500.md) | [488](/filings/0001193125-26-333762.md) |
| Total assets | $m | [334](/filings/0001437749-23-030613.md) | [347](/filings/0001437749-25-005637.md) | [354](/filings/0001437749-24-015899.md) | [363](/filings/0001437749-24-025466.md) | [377](/filings/0001437749-24-034124.md) | [552](/filings/0001193125-26-073360.md) | [556](/filings/0001437749-25-015479.md) | [578](/filings/0001437749-25-024936.md) | [598](/filings/0001193125-25-270981.md) | [616](/filings/0001193125-26-333762.md) | [630](/filings/0001193125-26-207500.md) | [641](/filings/0001193125-26-333762.md) |
| Current liabilities | $m | [29.0](/filings/0001437749-23-030613.md) | [29.9](/filings/0001437749-25-005637.md) | [26.8](/filings/0001437749-24-015899.md) | [25.4](/filings/0001437749-24-025466.md) | [29.3](/filings/0001437749-24-034124.md) | [30.6](/filings/0001193125-26-073360.md) | [24.7](/filings/0001437749-25-015479.md) | [30.8](/filings/0001437749-25-024936.md) | [33.3](/filings/0001193125-25-270981.md) | [36.3](/filings/0001193125-26-333762.md) | [33.4](/filings/0001193125-26-207500.md) | [29.9](/filings/0001193125-26-333762.md) |
| Total liabilities | $m | [45.4](/filings/0001437749-23-030613.md) | [48.9](/filings/0001437749-25-005637.md) | [45.5](/filings/0001437749-24-015899.md) | [43.5](/filings/0001437749-24-025466.md) | [46.0](/filings/0001437749-24-034124.md) | [215](/filings/0001193125-26-073360.md) | [208](/filings/0001437749-25-015479.md) | [215](/filings/0001437749-25-024936.md) | [219](/filings/0001193125-25-270981.md) | [222](/filings/0001193125-26-333762.md) | [223](/filings/0001193125-26-207500.md) | [220](/filings/0001193125-26-333762.md) |
| Shareholders' equity | $m | [289](/filings/0001437749-24-034124.md) | [298](/filings/0001193125-26-073360.md) | [309](/filings/0001193125-25-270981.md) | [320](/filings/0001193125-25-270981.md) | [331](/filings/0001193125-25-270981.md) | [337](/filings/0001193125-26-333762.md) | [348](/filings/0001193125-26-333762.md) | [363](/filings/0001193125-26-333762.md) | [379](/filings/0001193125-25-270981.md) | [394](/filings/0001193125-26-333762.md) | [407](/filings/0001193125-26-333762.md) | [420](/filings/0001193125-26-333762.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [11.8 d](/filings/0001437749-24-034124.md) | [10.7 d](/filings/0001193125-26-073360.md) | [5.1](/filings/0001437749-25-015479.md) | [9.6 d](/filings/0001437749-25-024936.md) | [14.2 d](/filings/0001193125-25-270981.md) | [15.2 d](/filings/0001193125-26-073360.md) | [9.0](/filings/0001193125-26-207500.md) | [20.3 d](/filings/0001193125-26-333762.md) | [28.8 d](/filings/0001193125-25-270981.md) | [23.2 d](/filings/0001193125-26-073360.md) | [15.1](/filings/0001193125-26-207500.md) | [16.0 d](/filings/0001193125-26-333762.md) |
| Capital expenditure | $m | [1.1 d](/filings/0001437749-24-034124.md) | [1.3 d](/filings/0001193125-26-073360.md) | [1.4](/filings/0001437749-25-015479.md) | [1.9 d](/filings/0001437749-25-024936.md) | [1.7 d](/filings/0001193125-25-270981.md) | [2.0 d](/filings/0001193125-26-073360.md) | [1.4](/filings/0001193125-26-207500.md) | [1.3 d](/filings/0001193125-26-333762.md) | [2.3 d](/filings/0001193125-25-270981.md) | [1.8 d](/filings/0001193125-26-073360.md) | [2.8](/filings/0001193125-26-207500.md) | [2.3 d](/filings/0001193125-26-333762.md) |
| Dividends paid | $m | [3.1 d](/filings/0001437749-24-034124.md) | [3.1 d](/filings/0001193125-26-073360.md) | [3.6](/filings/0001437749-25-015479.md) | [3.6 d](/filings/0001437749-25-024936.md) | [3.6 d](/filings/0001193125-25-270981.md) | [3.6 d](/filings/0001193125-26-073360.md) | [4.5](/filings/0001193125-26-207500.md) | [4.5 d](/filings/0001193125-26-333762.md) | [4.5 d](/filings/0001193125-25-270981.md) | [4.5 d](/filings/0001193125-26-073360.md) | [5.7](/filings/0001193125-26-207500.md) | [5.7 d](/filings/0001193125-26-333762.md) |
| Share repurchases | $m | [0.0 d](/filings/0001437749-24-034124.md) | [0.7 d](/filings/0001193125-26-073360.md) | [0.4](/filings/0001437749-25-015479.md) | [0.0 d](/filings/0001437749-25-024936.md) | [0.0 d](/filings/0001193125-25-270981.md) | [1.4 d](/filings/0001193125-26-073360.md) | [0.6](/filings/0001193125-26-207500.md) | [0.0 d](/filings/0001193125-26-333762.md) | [0.0 d](/filings/0001193125-25-270981.md) | [1.2 d](/filings/0001193125-26-073360.md) | [0.5](/filings/0001193125-26-207500.md) | [0.0 d](/filings/0001193125-26-333762.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [22.2](/filings/0001437749-23-030613.md) | [22.3](/filings/0001437749-24-015899.md) | [22.5](/filings/0001437749-24-025466.md) | [22.5](/filings/0001437749-24-034124.md) | [22.6](/filings/0001437749-25-015479.md) | [22.7](/filings/0001437749-25-024936.md) | [22.8](/filings/0001193125-25-270981.md) | [22.9](/filings/0001193125-26-207500.md) | [22.9](/filings/0001193125-26-333762.md) | [24.4](/filings/0001193125-25-270981.md) | [23.0](/filings/0001193125-26-207500.md) | [24.5](/filings/0001193125-26-333762.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 22,869,257 at 2026-08-02, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-333762.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.